Iowa Attorney General Tom Miller announced today that Iowa, along with 40 other states and the District of Columbia, has obtained court orders settling a consumer protection investigation of the marketing of Rapamune, a drug used to prevent organ rejection in kidney transplants.

Under the settlement, Pfizer Inc., as corporate parent of Wyeth Pharmaceuticals Inc., will pay the state $537,391 and change the way the company promotes the drug. Rapamune has serious side effects when used to prevent organ rejection in transplants of organs other than kidneys.

Miller said that the settlement is the latest in a series of cases involving drug-makers promoting drugs for "off-label" uses. The payment to Iowa will go into the state consumer litigation and education fund.